NCT01919619 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 41
- units
- Participants
- groups
- description
- Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
- id
- BG000
- title
- Autologous -Treatment (Lenalidomide and Ipilimumab)
- description
- Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
- id
- BG001
- title
- Allogeneic - Treatment (Lenalidomide and Ipilimumab)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 33
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 8
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 15
- title
- Female
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 26
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 37
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 41
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 41
- units
- Participants
- groups
- description
- Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
- id
- BG000
- title
- Autologous -Treatment (Lenalidomide and Ipilimumab)
- description
- Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
- id
- BG001
- title
- Allogeneic - Treatment (Lenalidomide and Ipilimumab)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 33
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 8
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 15
- title
- Female
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 26
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 37
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 41
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle